Patent granted in India to JINA PHARMACEUTICALS, INC. — research analysis
Identify the historical Jina Pharmaceuticals Indian patent
The preserved GIPResearch article reports Indian patent 381262, titled Improved Pharmaceutical Composition of Endoxifen & Preparation Thereof, in the name of Jina Pharmaceuticals, Inc., and cites the Patent Office journal dated 12 November 2021. This is the historical source attribution; the actual journal entry, application number, complete grant specification and current status have not been independently matched in an official live register during this review. The report should therefore present 381262 as a documented legacy identification requiring official confirmation, not as proof that an enforceable Indian monopoly currently exists. Before any transactional or infringement use, retrieve the current register extract, granted claims, chain of title, renewal entries and material subsequent proceedings.
Source for this point: GIPResearch.com — preserved Jina Pharmaceuticals historical article (Original site assertion; not independent patent-office verification).
Explain the described dosage-form architecture
The legacy summary identifies a multilayer pharmaceutical composition comprising an endoxifen-containing core, a surrounding sub-coat, an enteric coat and, optionally, a color coat. These structural elements suggest a formulation or delivery-system focus rather than a claim to every use of endoxifen as a molecule. But the granted independent claims may include additional material, structural or processing limitations that cannot be established from a short website summary. A technical review should identify the purpose of each layer, the manufacturing process, dissolution conditions, stability observations and any distinction from known enteric-coated formulations. Endoxifen itself is a named compound; the patentability question concerns the actual claimed technical features and supporting evidence.
Compare a layered formulation with the nearest prior art
The first search should cover endoxifen dosage forms, enteric-coated compositions, protective sub-coats, salts, release profiles and related manufacturing methods. Search public patent publications by chemical names, applicant, invention title, date and coating terminology. A claim chart should identify whether the alleged improvement is associated with specific coat materials, layer thickness, release conditions or stable manufacturing results. It is not enough to identify enteric coating as a known technique or claim that the combination is novel without an exact comparison. The dossier should distinguish earlier disclosures of endoxifen from earlier disclosures of the same multilayer delivery architecture. Each relevant document should be mapped to individual claimed features and dates.
Examine evidence behind the reported section 3(d) arguments
The original article says the examiner objected under section 3(d) and that the applicant argued that the dosage form differed from known derivatives and offered improved technical or efficacy-related characteristics. That narrative must be checked against the prosecution file before being presented as the Controller's reasoning. The statute addresses specified new forms and uses of known substances, while other requirements concern inventive step, novelty and sufficiency. An argument submitted by an applicant is not identical to a finding by the patent office. A robust research table should show the precise objection, referenced prior art, applicant's evidence, claim amendments and final recorded grounds for grant or refusal. Unsupported conclusions should be removed.
Source for this point: IP India — Patents Act 1970, section 3 (Official statute).
Keep formulation effects separate from therapeutic outcomes
An enteric coat may influence where or when a dosage form releases an active ingredient; a sub-coat can serve functions such as separating components or protecting the core. These are possible technical roles, not verified descriptions of the particular granted formulation. Dissolution curves, stability testing and manufacturing repeatability provide different types of evidence from clinical outcome studies. A patent's formulation examples do not demonstrate patient-level efficacy or drug authorization unless backed by separate appropriate research and regulator findings. The revised article should avoid implying that an applicant's clinical comparison establishes superiority without identifying its study design. Patent prosecution and medicines regulation should be documented independently, even when both concern the same product.
Reconstruct ownership and family context carefully
A patent-family search may identify overseas endoxifen filings, but the report must not assume every endoxifen document belongs to Jina Pharmaceuticals or to the same priority family. Match earliest priority identifiers, named inventors, application numbers and specific technical subject matter before asserting a family link. Some later endoxifen-related US documents concern different assignees and sustained-release formulations; those are not automatically equivalents to the reported Indian application. The report should record the national filing route, publication chronology, granted claim version, recorded assignments and current legal events. Official ownership and status matter because a historical grant notice cannot establish rights still held or enforceable five years later.
Create a claim-to-formulation evidence worksheet
The main information-gain element should be a layered-dosage-form table. Rows should cover endoxifen core, intermediate sub-coat, enteric layer, optional external coat and preparation steps; columns should identify exact claim language, disclosed composition, experimental evidence, closest prior formulation and unanswered questions. A companion table can list different types of dissolution and stability tests, explaining what each test can and cannot prove about the technical claim. This avoids confusing a structural diagram with functional validation. Where data are absent from the available source, write 'not verified' rather than inserting plausible materials or performance values from general pharmaceutical practice.
Conclude with a bounded patent dossier
The existing article supplies a specific historical Indian patent number and a useful preliminary description of a layered endoxifen composition. An evidence-ready update needs the official grant record, patent-family identification, final claim text, full examiner correspondence and current legal-status verification. It also needs research into the actual comparative formulation examples before describing any technical advantage. No conclusion about product clearance, therapeutic efficacy, market exclusivity or enforcement can be drawn solely from the historical summary. The practical output for a prospective licensee or competitor is a list of identified patent facts and missing documents, followed by a claim-specific legal analysis when the necessary official records are available.
Do not substitute unrelated endoxifen patents as evidence
Search engines can return multiple endoxifen documents from different applicants, countries and years. A US patent concerning sustained-release endoxifen does not automatically correspond to an older Indian patent on a multilayer enteric-coated dosage form. Family identity depends on common priority and filing records, not on the compound name alone. A comparison should identify the precise formulation and claim dependencies in each document. This distinction is commercially important because one product may involve more than one right, and a favorable finding about one formulation says nothing definitive about other compounds or routes. The revised report should keep its historical Indian identifier while adding only verified family connections and carefully labeled research leads.
Original evidence-to-decision matrix
| Research dimension | Evidence to inspect | Interpretation boundary |
|---|---|---|
| Reported grant | Indian 381262 in historical page | Official status and family record pending |
| Dosage architecture | Core, sub-coat, enteric coat descriptions | Claim amendments may add limitations |
| Technical effect | Dissolution and stability studies | Not a clinical trial result |
Research readiness checklist
- Obtain official 381262 specification and ownership entries.
- Map each dosage layer to the actual granted claim.
- Distinguish dissolution tests from efficacy claims.
- Do not merge unrelated endoxifen patent families.
References and primary sources
- GIPResearch.com — preserved Jina Pharmaceuticals historical article. Original site assertion; not independent patent-office verification.
- IP India — Patents Act 1970, section 3. Official statute.
- USPTO MPEP §2164 — Enablement. Official examination manual.
General research only. Any current grant, claim, ownership, legal status or professional opinion requires verification of official records and the facts of the particular matter. Full disclaimer


How to patent fintech inventions
Gen AI Innovations
What is Extended Reality
How to patent artificial intelligence based innovations
Patent claim drafting